| Literature DB >> 24250381 |
Ramin Miri1, Katayoun Javidnia, Zahra Amirghofran, Seyyed Hossein Salimi, Zahra Sabetghadam, Savis Meili, Ahmad Reza Mehdipour.
Abstract
The 1,4-dihydropyridine (DHP) derivatives are a known class of calcium channel blockers. Some derivatives of DHP showed significant cytotoxicity. It was shown that this effect may not be the result of interaction with Ca(2+) channels. In this study, we performed an investigation about the intrinsic cytotoxicity of some derivatives of DHP containing nitroimidazole moiety on their C4 position on four different cancer cell lines (Raji, K562, Fen and HeLa). The result showed that these compounds had moderate-good cytotoxic activity. In addition, QSAR model shows the importance of N atom in cytotoxicity; Ca(2+) channels.Entities:
Keywords: 1,4-Dihydropyridines; Cytotoxicity; MTT assay; Nitroimidazole
Year: 2011 PMID: 24250381 PMCID: PMC3813032
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Structure of DHP derivatives used in this study and their calcium channel antagonist activity.
|
|
Cell growth inhibitory activity of compounds a-e in-vitro (IC30).
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
| |||
| 100 < | 33.1 | 100 < | 58.3 |
| ||
| 100 < | 57.8 | 100 < | 1 > |
| ||
| 100 < | 37.3 | 100 < | 32.5 |
| ||
| 100 < | 58.9 | 100 < | 1 > |
| ||
| 100< | 71.1 | 100 < | 100< |
| ||
| 1 > | 1 > | 1 > | 1 > |
| ||
| 12.6 | 10.5 | 100 < | 12.3 |
| ||
| 5.6 | 1.4 | 1.3 | 1.4 |
| ||
| 5.4 | 1.1 | 1.1 | 1.1 |
| ||
| 3.1 | 1 > | 1 > | 1 |
| ||
| 100 < | 100 < | 100 < | 100 < |
| ||
| 1.7 | 1.2 | 1.2 | 1.4 |
| ||
| 1 > | 1 > | 1 > | 1 > |
| ||
| 1 > | 1 > | 1 > | 1 > |
| ||
| 3.1 | 1.3 | 2.1 | 1.1 |
| ||
| 3.4 | 1> | 1 > | 1 |
| ||
| 100 < | 100 < | 1 > | 100< |
| ||
| 1 > | 1 > | 1 > | 1 > |
| ||
| 100 < | 100 < | 100 < | 100 < |
| ||
a: IC30 is the molar concentration causing 30% growth inhibition of tumor cells
Cell growth inhibitory activity of compounds a-e in-vitro (IC15
|
| |||||
|---|---|---|---|---|---|
| HeLa | Fen | K562 | Raji | Compound | |
| 38.1 | < 1 | 41.8 | < 1 | ||
| 54.7 | < 1 | 84.0 | < 1 |
| |
| 38.8 | < 1 | 6.2 | < 1 |
| |
| 45.5 | < 1 | 20.2 | < 1 |
| |
| 72.4 | < 1 | < 1 | < 1 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| < 1 | < 1 | 4.1 | < 1 |
| |
| 1.2 | < 1 | < 1 | < 1 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| 53.5 | 51.5 | 52.5 | > 100 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| 35.5 | 44.7 | 44.4 | 22.4 |
| |
| < 1 | < 1 | < 1 | < 1 |
| |
| 81.1 | 71.4 | 80.4 | 92.4 |
| |
a: IC15 is the molar concentration causing 15% growth inhibition of tumor cells
Cell growth inhibitory activity of compounds a-e in-vitro (IC50).
|
| ||||
|---|---|---|---|---|
|
|
|
|
|
|
| > 100 | > 100 | > 100 | > 100 |
|
| > 100 | > 100 | > 100 | > 100 |
|
| > 100 | > 100 | > 100 | > 100 |
|
| > 100 | > 100 | > 100 | > 100 |
|
| > 100 | > 100 | > 100 | > 100 |
|
| 5.4 | 4.1 | 2.8 | 4.0 |
|
| 68.3 | 56.3 | > 100 | 69.3 |
|
| 30.9 | 15.1 | 14.1 | 15.4 |
|
| 29.4 | 6.8 | 3.0 | 7.1 |
|
| 25.3 | 4.3 | 3.8 | 8.1 |
|
| > 100 | > 100 | > 100 | > 100 |
|
| 14.9 | 14.3 | 14.3 | 14.1 |
|
| < 1 | < 1 | < 1 | < 1 |
|
| 2.8 | 2.4 | 2.5 | 3.1 |
|
| 23.4 | 8.8 | 20.2 | 8.4 |
|
| 28.5 | 7.2 | 3.3 | 8.2 |
|
| > 100 | > 100 | > 100 | > 100 |
|
| < 1 | < 1 | < 1 | < 1 |
|
| > 100 | > 100 | > 100 | > 100 |
|
a: IC50 is the molar concentration causing 50% growth inhibition of tumor cells.